Raphael Mwamtsi Lwembe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Raphael Mwamtsi Lwembe has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Alex Maiyo
Centre for Virus Research (CVR) Kenya Medical Research Institute (KEMRI) Nairobi Kenya kemri.org
2 shared publications- Asma A. Adan
Centre for Microbiology Research-Kenya medical Research Institute, P.O Box 54840-00200, Nairobi, Kenya
2 shared publications - Brad Gautney
Global Health Innovations, Dallas, TX, USA
2 shared publications - Catherine Wexler
Department of Family Medicine and Community Health, University of Kansas Medical Center, Kansas City, USA
2 shared publications - Edward K. Maina
Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya
2 shared publications - Emily A. Hurley
Division of Health Services and Outcomes Research, Children’s Mercy Kansas City, Kansas City, USA
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in AIDS Research and Treatment
- Vol. 2026 (1) , 5621772
Effect of Antiretroviral Therapy, Immune Dysregulation, and COVID‐19 Vaccination on SARS‐CoV‐2 Outcomes in PLWHA in Kenya
Background: People living with HIV (PLWHA) may experience increased vulnerability to SARS‐CoV‐2 infection and severe COVID‐19 due to immune dysregulation, comorbidities, and treatment adherence challenges. Kenya has over 1.4 million PLWHA. However, only a few have been reported with severe COVID‐19, suggesting potential protective roles of antiretroviral therapy (ART), management of comorbidities, and COVID‐19 vaccination. Methods: This study was conducted across high HIV‐prevalence regions in Kenya (Nakuru, Malindi/Mariakani, and Kisumu). A cross‐sectional survey evaluates clinical characteristics and self‐reported COVID‐19 vaccination outcomes among 303 PLWHA. Quantitative data were collected through structured questionnaires and clinical records. Associations between ART, immune markers (CD4/CD8 counts; viral load), COVID‐19 vaccination, and SARS‐CoV‐2 infection and severity were tested using Chi‐square and Fisher’s exact tests. Results: An analysis of 303 participants (70.6% female, median age 40) revealed an 86.5% COVID‐19 vaccination rate and 94.1% ART adherence. Only 9.2% reported prior SARS‐CoV‐2 infection, mostly mild, potentially indicating underreporting or asymptomatic cases. Interestingly, missing ART doses were significantly associated with contracting SARS‐CoV‐2 ( p = 0.03). Furthermore, all participants reporting or demonstrating SARS‐CoV‐2 infection were vaccinated, compared to 85.1% of uninfected participants ( p = 0.014). Due to incomplete health records, data for CD4 counts were available for only 7.6% of participants ( n = 23), limiting conclusions regarding immune dysregulation. Conclusion: Low COVID‐19 rates were observed. All cases occurred in vaccinated participants, likely reflecting health‐seeking bias rather than vaccine failure. Missing ART doses were significantly associated with infection. Optimal risk mitigation requires integrated strategies prioritizing both high vaccine coverage and strict ART adherence.
- 1 January 2026
- Published by Wiley in AIDS Research and Treatment
- Vol. 2026 (1) , 5621772
Open AccessEffect of Antiretroviral Therapy, Immune Dysregulation, and COVID‐19 Vaccination on SARS‐CoV‐2 Outcomes in PLWHA in Kenya
Background: People living with HIV (PLWHA) may experience increased vulnerability to SARS‐CoV‐2 infection and severe COVID‐19 due to immune dysregulation, comorbidities, and treatment adherence challenges. Kenya has over 1.4 million PLWHA. However, only a few have been reported with severe COVID‐19, suggesting potential protective roles of antiretroviral therapy (ART), management of comorbidities, and COVID‐19 vaccination. Methods: This study was conducted across high HIV‐prevalence regions in Kenya (Nakuru, Malindi/Mariakani, and Kisumu). A cross‐sectional survey evaluates clinical characteristics and self‐reported COVID‐19 vaccination outcomes among 303 PLWHA. Quantitative data were collected through structured questionnaires and clinical records. Associations between ART, immune markers (CD4/CD8 counts; viral load), COVID‐19 vaccination, and SARS‐CoV‐2 infection and severity were tested using Chi‐square and Fisher’s exact tests. Results: An analysis of 303 participants (70.6% female, median age 40) revealed an 86.5% COVID‐19 vaccination rate and 94.1% ART adherence. Only 9.2% reported prior SARS‐CoV‐2 infection, mostly mild, potentially indicating underreporting or asymptomatic cases. Interestingly, missing ART doses were significantly associated with contracting SARS‐CoV‐2 ( p = 0.03). Furthermore, all participants reporting or demonstrating SARS‐CoV‐2 infection were vaccinated, compared to 85.1% of uninfected participants ( p = 0.014). Due to incomplete health records, data for CD4 counts were available for only 7.6% of participants ( n = 23), limiting conclusions regarding immune dysregulation. Conclusion: Low COVID‐19 rates were observed. All cases occurred in vaccinated participants, likely reflecting health‐seeking bias rather than vaccine failure. Missing ART doses were significantly associated with infection. Optimal risk mitigation requires integrated strategies prioritizing both high vaccine coverage and strict ART adherence.
- Open Access
- 3 June 2024
- Published by MedCrave Group Kft. in Journal of Human Virology & Retrovirology
- Vol. 11 (1) , 31-34
Incidence and severity of COVID-19 among HIV positive patients with existing co-morbidities
Background: The extent to which people living with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) (PLWHA) are susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and their risk of mortality is not well documented. PLWHA have a distinct profile because of their immune system alterations from chronic HIV infection and their use of antiretroviral therapy, some of which have been investigated for treating coronavirus disease 2019 (COVID-19). The situation becomes even worse when the HIV patient has existing comorbidities. Methods: Confirmed disease was defined as any patient with a positive antigen test, reverse transcriptase polymerase chain reaction, or serology for SARS-CoV-2. We compared the characteristics of patients with mild disease (asymptomatic included) with those with moderate or severe disease (requiring admission). Results: Older participants were more likely to have comorbidities, with diabetes and hypertension being the most common. It also found that the severity of these comorbidities worsened during the COVID-19 pandemic, leading to an increase in vaccine uptake among those with pre-existing conditions. Additionally, some participants developed new comorbidities as a result of COVID-19, possibly due to weakened immune systems. Conclusion: Individuals with HIV face an increased risk of severe SARS-CoV-2 infection because of their weakened immune systems. Those with HIV/AIDS who also have comorbidities like diabetes and hypertension are at an even greater risk.
- 3 June 2024
- Published by MedCrave Group Kft. in Journal of Human Virology & Retrovirology
- Vol. 11 (1) , 31-34
Open AccessIncidence and severity of COVID-19 among HIV positive patients with existing co-morbidities
Background: The extent to which people living with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) (PLWHA) are susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and their risk of mortality is not well documented. PLWHA have a distinct profile because of their immune system alterations from chronic HIV infection and their use of antiretroviral therapy, some of which have been investigated for treating coronavirus disease 2019 (COVID-19). The situation becomes even worse when the HIV patient has existing comorbidities. Methods: Confirmed disease was defined as any patient with a positive antigen test, reverse transcriptase polymerase chain reaction, or serology for SARS-CoV-2. We compared the characteristics of patients with mild disease (asymptomatic included) with those with moderate or severe disease (requiring admission). Results: Older participants were more likely to have comorbidities, with diabetes and hypertension being the most common. It also found that the severity of these comorbidities worsened during the COVID-19 pandemic, leading to an increase in vaccine uptake among those with pre-existing conditions. Additionally, some participants developed new comorbidities as a result of COVID-19, possibly due to weakened immune systems. Conclusion: Individuals with HIV face an increased risk of severe SARS-CoV-2 infection because of their weakened immune systems. Those with HIV/AIDS who also have comorbidities like diabetes and hypertension are at an even greater risk.
- Open Access
- 10 February 2022
- Published by Wiley in Advances in Virology
- Vol. 2022, 1-7
Antiretroviral (ARV) Drug Resistance and HIV-1 Subtypes among Injecting Drug Users in the Coastal Region of Kenya
HIV-1 genetic diversity results into the development of widespread drug-resistant mutations (DRMs) for the first-line retroviral therapy. Nevertheless, few studies have investigated the relationship between DRMs and HIV-1 subtypes among HIV-positive injecting drug users (IDUs). This study therefore determined the association between HIV-1 genotypes and DRMs among the 200 IDUs. Stanford HIV Drug Resistance Database was used to interpret DRMs. The five HIV-1 genotypes circulating among the IDUs were A1 (25 (53.2)), A2 (2 (4.3)), B (2 (4.3)), C (9 (19.1)), and D (9 (19.1)). The proportions of DRMs were A1 (12 (52.2)), A2 (1 (4.3)), B (0 (0.0)), C (5 (21.7)), and D (5 (21.7)). Due to the large proportion of drug resistance across all HIV-1 subtypes, surveillance and behavioral studies need to be explored as IDUs may be spreading the drug resistance to the general population. In addition, further characterization of DRMs including all the relevant clinical parameters among the larger population of IDUs is critical for effective drug resistance surveillance.
- 10 February 2022
- Published by Wiley in Advances in Virology
- Vol. 2022, 1-7
Open AccessAntiretroviral (ARV) Drug Resistance and HIV-1 Subtypes among Injecting Drug Users in the Coastal Region of Kenya
HIV-1 genetic diversity results into the development of widespread drug-resistant mutations (DRMs) for the first-line retroviral therapy. Nevertheless, few studies have investigated the relationship between DRMs and HIV-1 subtypes among HIV-positive injecting drug users (IDUs). This study therefore determined the association between HIV-1 genotypes and DRMs among the 200 IDUs. Stanford HIV Drug Resistance Database was used to interpret DRMs. The five HIV-1 genotypes circulating among the IDUs were A1 (25 (53.2)), A2 (2 (4.3)), B (2 (4.3)), C (9 (19.1)), and D (9 (19.1)). The proportions of DRMs were A1 (12 (52.2)), A2 (1 (4.3)), B (0 (0.0)), C (5 (21.7)), and D (5 (21.7)). Due to the large proportion of drug resistance across all HIV-1 subtypes, surveillance and behavioral studies need to be explored as IDUs may be spreading the drug resistance to the general population. In addition, further characterization of DRMs including all the relevant clinical parameters among the larger population of IDUs is critical for effective drug resistance surveillance.
- Open Access
- 26 January 2021
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 19 (1) , 14-26
A Review of Current Strategies Towards the Elimination of Latent HIV-1 and Subsequent HIV-1 Cure
Background: During the past 35 years, highly effective ART has saved the lives of millions of people worldwide by suppressing viruses to undetectable levels. However, this does not translate to the absence of viruses in the body as HIV persists in latent reservoirs. Indeed, rebounded HIV has been recently observed in the Mississippi and California infants previously thought to have been cured. Hence, much remains to be learned about HIV latency, and the search for the best strategy to eliminate the reservoir is the direction current research is taking. A systems-level approach that fully recapitulates the dynamics and complexity of HIV-1 latency In vivo and is applicable in human therapy is prudent for HIV eradication to be more feasible. Objectives: The main barriers preventing the cure of HIV with antiretroviral therapy have been identified, progress has been made in the understanding of the therapeutic targets to which potentially eradicating drugs could be directed, integrative strategies have been proposed, and clinical trials with various alternatives are underway. The aim of this review is to provide an update on the main advances in HIV eradication, with particular emphasis on the obstacles and the different strategies proposed. The core challenges of each strategy are highlighted and the most promising strategy and new research avenues in HIV eradication strategies are proposed. Methods: A systematic literature search of all English-language articles published between 2015 and 2019, was conducted using MEDLINE (PubMed) and Google scholar. Where available, medical subject headings (MeSH) were used as search terms and included: HIV, HIV latency, HIV reservoir, latency reactivation, and HIV cure. Additional search terms consisted of suppression, persistence, establishment, generation, and formation. A total of 250 articles were found using the above search terms. Out of these, 89 relevant articles related to HIV-1 latency establishment and eradication strategies were collected and reviewed, with no limitation of study design. Additional studies (commonly referenced and/or older and more recent articles of significance) were selected from bibliographies and references listed in the primary resources. Results : In general, when exploring the literature, there are four main strategies heavily researched that provide promising strategies to the elimination of latent HIV: Haematopoietic Stem-Cell Transplantation, Shock and Kill Strategy, Gene-specific transcriptional activation using RNA-guided CRISPR-Cas9 system, and Block and Lock strategy. Most of the studies of these strategies are applicable in vitro, leaving many questions about the extent to which, or if any, these strategies are applicable to complex picture In vivo. However, the success of these strategies at least shows, in part, that HIV-1 can be cured, though some strategies are too invasive and expensive to become a standard of care for all HIV-infected patients. Conclusion: Recent advances hold promise for the ultimate cure of HIV infection. A systems-level approach that fully recapitulates the dynamics and complexity of HIV-1 latency In vivo and applicable in human therapy is prudent for HIV eradication to be more feasible. Future studies aimed at achieving a prolonged HIV remission state are more likely to be successful if they focus on a combination strategy, including the block and kill, and stem cell approaches. These strategies propose a functional cure with minimal toxicity for patients. It is believed that the cure of HIV infection will be attained in the short term if a strategy based on purging the reservoirs is complemented with an aggressive HAART strategy.
- 26 January 2021
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 19 (1) , 14-26
Open AccessA Review of Current Strategies Towards the Elimination of Latent HIV-1 and Subsequent HIV-1 Cure
Background: During the past 35 years, highly effective ART has saved the lives of millions of people worldwide by suppressing viruses to undetectable levels. However, this does not translate to the absence of viruses in the body as HIV persists in latent reservoirs. Indeed, rebounded HIV has been recently observed in the Mississippi and California infants previously thought to have been cured. Hence, much remains to be learned about HIV latency, and the search for the best strategy to eliminate the reservoir is the direction current research is taking. A systems-level approach that fully recapitulates the dynamics and complexity of HIV-1 latency In vivo and is applicable in human therapy is prudent for HIV eradication to be more feasible. Objectives: The main barriers preventing the cure of HIV with antiretroviral therapy have been identified, progress has been made in the understanding of the therapeutic targets to which potentially eradicating drugs could be directed, integrative strategies have been proposed, and clinical trials with various alternatives are underway. The aim of this review is to provide an update on the main advances in HIV eradication, with particular emphasis on the obstacles and the different strategies proposed. The core challenges of each strategy are highlighted and the most promising strategy and new research avenues in HIV eradication strategies are proposed. Methods: A systematic literature search of all English-language articles published between 2015 and 2019, was conducted using MEDLINE (PubMed) and Google scholar. Where available, medical subject headings (MeSH) were used as search terms and included: HIV, HIV latency, HIV reservoir, latency reactivation, and HIV cure. Additional search terms consisted of suppression, persistence, establishment, generation, and formation. A total of 250 articles were found using the above search terms. Out of these, 89 relevant articles related to HIV-1 latency establishment and eradication strategies were collected and reviewed, with no limitation of study design. Additional studies (commonly referenced and/or older and more recent articles of significance) were selected from bibliographies and references listed in the primary resources. Results : In general, when exploring the literature, there are four main strategies heavily researched that provide promising strategies to the elimination of latent HIV: Haematopoietic Stem-Cell Transplantation, Shock and Kill Strategy, Gene-specific transcriptional activation using RNA-guided CRISPR-Cas9 system, and Block and Lock strategy. Most of the studies of these strategies are applicable in vitro, leaving many questions about the extent to which, or if any, these strategies are applicable to complex picture In vivo. However, the success of these strategies at least shows, in part, that HIV-1 can be cured, though some strategies are too invasive and expensive to become a standard of care for all HIV-infected patients. Conclusion: Recent advances hold promise for the ultimate cure of HIV infection. A systems-level approach that fully recapitulates the dynamics and complexity of HIV-1 latency In vivo and applicable in human therapy is prudent for HIV eradication to be more feasible. Future studies aimed at achieving a prolonged HIV remission state are more likely to be successful if they focus on a combination strategy, including the block and kill, and stem cell approaches. These strategies propose a functional cure with minimal toxicity for patients. It is believed that the cure of HIV infection will be attained in the short term if a strategy based on purging the reservoirs is complemented with an aggressive HAART strategy.
- Open Access
- 1 August 2020
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 97, 151-158
Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya
- 1 August 2020
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 97, 151-158
Open AccessIncidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya
- Open Access
- 22 August 2018
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 6 (8) , e169
Implementing eHealth Technology to Address Gaps in Early Infant Diagnosis Services: Qualitative Assessment of Kenyan Provider Experiences
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.
- 22 August 2018
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 6 (8) , e169
Open AccessImplementing eHealth Technology to Address Gaps in Early Infant Diagnosis Services: Qualitative Assessment of Kenyan Provider Experiences
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.
- Open Access
- 3 January 2018
- Published by JMIR Publications Inc. in JMIR Preprints
Implementing eHealth Technology to Address Gaps in Early Infant Diagnosis Services: Qualitative Assessment of Kenyan Provider Experiences (Preprint)
BACKGROUND Literature suggests that electronic health (eHealth) interventions can improve the efficiency and accuracy of health service delivery and improve health outcomes and are generally well received by patients; however, there are limited data on provider experiences using eHealth interventions in resource-limited settings. The HIV Infant Tracking System (HITSystem) is an eHealth intervention designed to improve early infant diagnosis (EID) outcomes among HIV-exposed infants. OBJECTIVE We aimed to compare provider experiences with standard EID and HITSystem implementation at 6 Kenyan hospitals and 3 laboratories. The objective of this study was to better understand provider experiences implementing and using the HITSystem in order to assess facilitators and barriers that may impact adoption and sustainability of this eHealth intervention. METHODS As part of a randomized controlled trial to evaluate the HITSystem, we conducted semistructured interviews with 17 EID providers at participating intervention and control hospitals and laboratories. RESULTS Providers emphasized the perceived usefulness of the HITSystem, including improved efficiency in sample tracking and patient follow-up, strengthened communication networks among key stakeholders, and improved capacity to meet patient needs compared to standard EID. These advantages were realized from an intervention that providers saw as easy to use and largely compatible with workflow. However, supply stock outs and patient psychosocial factors (including fear of HIV status disclosure and poverty) provided ongoing challenges to EID service provision. Furthermore, slow or sporadic internet access and heavy workload prevented real-time HITSystem data entry for some clinicians. CONCLUSIONS Provider experiences with the HITSystem indicate that the usefulness of the HITSystem, along with the ease with which it is able to be incorporated into hospital workflows, contributes to its sustained adoption and use in Kenyan hospitals. To maximize implementation success, care should be taken in intervention design and implementation to ensure that end users see clear advantages to using the technology and to account for variations in workflows, patient populations, and resource levels by allowing flexibility to suit user needs. CLINICALTRIAL ClinicalTrials.gov NCT02072603; https://clinicaltrials.gov/ct2/show/NCT02072603 (Archived by WebCite at http://www.webcitation.org/71NgMCrAm)
- 3 January 2018
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessImplementing eHealth Technology to Address Gaps in Early Infant Diagnosis Services: Qualitative Assessment of Kenyan Provider Experiences (Preprint)
BACKGROUND Literature suggests that electronic health (eHealth) interventions can improve the efficiency and accuracy of health service delivery and improve health outcomes and are generally well received by patients; however, there are limited data on provider experiences using eHealth interventions in resource-limited settings. The HIV Infant Tracking System (HITSystem) is an eHealth intervention designed to improve early infant diagnosis (EID) outcomes among HIV-exposed infants. OBJECTIVE We aimed to compare provider experiences with standard EID and HITSystem implementation at 6 Kenyan hospitals and 3 laboratories. The objective of this study was to better understand provider experiences implementing and using the HITSystem in order to assess facilitators and barriers that may impact adoption and sustainability of this eHealth intervention. METHODS As part of a randomized controlled trial to evaluate the HITSystem, we conducted semistructured interviews with 17 EID providers at participating intervention and control hospitals and laboratories. RESULTS Providers emphasized the perceived usefulness of the HITSystem, including improved efficiency in sample tracking and patient follow-up, strengthened communication networks among key stakeholders, and improved capacity to meet patient needs compared to standard EID. These advantages were realized from an intervention that providers saw as easy to use and largely compatible with workflow. However, supply stock outs and patient psychosocial factors (including fear of HIV status disclosure and poverty) provided ongoing challenges to EID service provision. Furthermore, slow or sporadic internet access and heavy workload prevented real-time HITSystem data entry for some clinicians. CONCLUSIONS Provider experiences with the HITSystem indicate that the usefulness of the HITSystem, along with the ease with which it is able to be incorporated into hospital workflows, contributes to its sustained adoption and use in Kenyan hospitals. To maximize implementation success, care should be taken in intervention design and implementation to ensure that end users see clear advantages to using the technology and to account for variations in workflows, patient populations, and resource levels by allowing flexibility to suit user needs. CLINICALTRIAL ClinicalTrials.gov NCT02072603; https://clinicaltrials.gov/ct2/show/NCT02072603 (Archived by WebCite at http://www.webcitation.org/71NgMCrAm)